SpyGlass Pharma (SGP) News
NASDAQ: SGPHealth CareMedical/Dental InstrumentsUSD
30.43-0.35 (-1.14%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
SGP news summary
We found 4 recent headlines mentioning SpyGlass Pharma (SGP): 0 in the past week and 3 in the past 30 days, most often from GlobeNewswire, Nasdaq, Seeking Alpha. For price context, SGP is down 1.14% at $30.43. The most recent story, "SpyGlass Pharma Q3 Loss Widens", was published by Nasdaq on Nov 11, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest SpyGlass Pharma headlines
- SpyGlass Pharma Q3 Loss Widens(RTTNews) - SpyGlass Pharma, Inc. (SGP), a late-stage biopharmaceutical company focused on chronic eye conditions, reported wider third-quarter lossesNasdaq
- SpyGlass Pharma, Inc. GAAP EPS of -$0.73 misses by $0.09Seeking Alpha
- SpyGlass Pharma Reports Third Quarter 2026 Financial Results and Provides Corporate UpdatesIRVINE, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today reported recent business…GlobeNewswire
- SpyGlass Pharma Announces Positive 4-Year Data From First-in-Human Trial of Its Innovative BIM-IOL SystemGroundbreaking 4-year safety and efficacy results:GlobeNewswire